studi
immunogen
antisar
subunit
vaccin
compris
fragment
sar
coronaviru
sarscov
spike
protein
amino
acid
contain
receptorbind
domain
protein
fragment
purifi
cultur
supernat
stabli
transform
cell
secret
tag
version
protein
vaccin
given
subcutan
mice
salin
alum
adjuv
alum
plu
cpg
oligodeoxynucleotid
odn
mice
immun
adjuv
antigen
elicit
strong
antibodi
cellular
immun
respons
furthermor
ad
cpg
odn
alum
result
increas
antibodi
titer
higher
number
murin
splenocyt
mice
vaccin
deglycosyl
pngase
f
show
lower
neutral
antibodi
respons
similar
number
cell
spleen
find
suggest
carbohydr
import
immunogen
protein
fragment
provid
use
inform
design
effect
safe
sar
subunit
vaccin
sever
acut
respiratori
syndrom
sar
first
appear
guangdong
provinc
southern
china
novemb
newli
emerg
infecti
diseas
quickli
spread
countri
five
contin
along
intern
air
travel
rout
caus
largescal
outbreak
hong
kong
singapor
toronto
earli
world
health
organ
issu
global
alert
sar
march
support
author
affect
region
implement
epidemiolog
surveil
adher
infectioncontrol
procedur
help
contain
sar
outbreak
midjuli
howev
total
sar
case
associ
death
report
interim
within
month
whoissu
global
threat
alert
sar
novel
coronaviru
sarscov
identifi
etiolog
agent
genom
sequenc
like
coronavirus
sarscov
genom
singlestrand
plussens
rna
genom
nucleotid
predict
open
read
frame
orf
divid
two
group
clear
homolog
coronavirus
viral
function
propos
orf
includ
replicas
structur
gene
ii
clear
homolog
known
gene
often
refer
groupspecif
gene
coronaviru
spike
protein
larg
type
membran
glycoprotein
long
known
play
major
role
viral
entri
pathogenesi
protein
respons
bind
receptor
host
cell
play
import
role
membran
fusion
main
receptor
sarscov
angiotensinconvert
enzym
shown
amino
acid
sarscov
protein
suffici
bind
protein
attract
target
therapeut
vaccin
develop
monoclon
antibodi
protein
neutral
sarscov
infect
moreov
protein
shown
induc
serum
neutral
antibodi
confer
protect
immun
sarscov
challeng
although
sar
humantohuman
transmiss
stop
develop
sar
vaccin
remain
public
health
prioriti
given
possibl
reemerg
sever
potenti
strategi
consid
vaccin
sarscov
includ
wholekil
viru
vaccin
viral
vector
vaccin
recombin
subunit
vaccin
dnabas
vaccin
previous
report
develop
two
sar
vaccin
candid
wholekil
viru
two
adenovirusbas
vector
consist
sarscov
n
protein
induc
serum
neutral
antibodi
inhibit
pulmonari
sarscov
replic
report
describ
third
candid
sarscov
subunit
vaccin
compris
residu
protein
produc
bioreactorbas
mammalian
cell
express
system
protein
formul
differ
adjuv
evalu
immunogen
murin
model
fulli
glycosyl
form
deglycosyl
pngase
f
express
vector
incorpor
codonoptim
version
sarscov
fragment
mammalian
transin
secret
signal
ntermin
proteina
pra
purif
tag
tobacco
etch
viru
tev
proteas
cleavag
site
gener
use
plasmid
clontech
cell
transfect
calcium
phosphat
method
bulk
cultur
resist
puromycin
gml
expand
media
assay
secret
protein
level
western
blot
analysi
use
anti
pra
antibodi
sigma
product
fusion
protein
scaledup
adher
cell
l
new
brunswick
celligen
bioreactor
use
g
fibracel
disk
new
brunswick
scientif
bioreactor
run
perfus
mode
use
chossfm
ii
media
gibco
supplement
fetal
bovin
serum
fb
gl
glucos
non
essenti
amino
acid
gibco
mgl
aprotinin
bioshop
burlington
ontario
mgl
puromycin
bioshop
burlington
ontario
penicillinstreptomycin
gibco
flow
rate
lday
harvest
media
concentr
fusion
protein
purifi
iggsepharos
amersham
bioscienc
affin
chromatographi
fusion
protein
digest
tev
proteas
ratio
ww
c
h
remov
ntermin
pra
fusion
tag
result
clone
strategi
tev
proteas
cleavag
result
protein
fragment
contain
four
addit
amino
acid
ggrp
nterminu
fragment
purifi
hitrap
phenyl
hydrophob
interact
chromatographi
hitrap
q
anion
exchang
chromatographi
superdex
gel
filtrat
chromatographi
amersham
bioscienc
portion
purifi
deglycosyl
pngase
f
digest
ratio
ww
c
h
purifi
superdex
gel
filtrat
chromatographi
follow
gel
filtrat
natur
glycosyl
pngase
f
deglycosyl
sampl
dialyz
phosphat
buffer
salin
pb
without
cacl
mgcl
concentr
mgml
inject
six
eightweekold
femal
mice
purchas
tacon
farm
germantown
ny
four
group
five
mice
immun
subcutan
twice
interv
one
follow
formul
g
protein
salin
g
protein
alum
alhydrogel
superfo
biosector
lg
protein
give
mg
al
mg
g
protein
alum
cpg
oligodeoxynucleotid
odn
qiagen
dose
gmous
g
protein
alum
cpg
odn
fifth
group
mice
immun
salin
sera
collect
day
mice
sacrif
day
sera
test
standard
viru
neutral
assay
previous
describ
briefli
serum
sampl
heat
c
min
duplic
serial
twofold
dilut
incub
pfu
sarscov
strain
h
ad
monolay
cell
cultur
examin
h
characterist
viral
cpe
cellular
immun
respons
sarscov
assess
elispot
assay
use
murin
splenocyt
unifilt
plate
coat
overnight
mlwell
gml
rat
antimous
bd
pharmingen
wash
rpmi
life
technolog
contain
fb
incub
triplic
splenocyteswel
ml
rpmi
media
fb
contain
gml
protein
fragment
h
incub
c
co
incub
plate
wash
five
time
pb
ph
contain
tween
incub
overnight
c
biotinyl
rat
antimous
antibodi
bd
pharmingen
mlwell
gml
wash
pb
contain
tween
plate
incub
h
dilut
streptavidinalkalin
phosphatas
jackson
immunoresearch
eight
wash
water
plate
develop
sigma
fast
phosphatenitro
blue
tetrazolium
develop
stop
wash
tap
water
plate
airdri
number
spot
count
light
microscop
ten
microgram
sarscov
infect
cell
lysat
sampl
buffer
run
sdspage
transfer
nitrocellulos
membran
nonspecif
bind
site
membran
block
nonfat
dri
milk
biorad
protein
detect
expos
membran
pool
mous
sera
dilut
follow
antimous
igg
conjug
alkalin
phosphatas
blot
develop
use
ap
conjug
substrat
kit
biorad
total
sarscovspecif
igg
igg
isotyp
titer
sera
immun
mice
measur
elisa
describ
previous
briefli
plate
coat
overnight
ml
per
well
gml
antigen
purifi
inactiv
sarscov
protein
wash
plate
addit
sera
color
develop
perform
previous
describ
statist
signific
assess
use
oneway
anova
follow
tukeytest
differ
mean
valu
vaccin
group
consid
signific
pvalu
recent
studi
indic
immun
respons
ntermin
segment
sarscov
protein
confer
protect
sarscov
infect
therefor
use
human
cell
cultur
system
express
proteina
tag
fragment
protein
amino
acid
secret
glycosyl
protein
could
readili
purifi
nativ
condit
cleavag
tag
protein
purifi
aliquot
analyz
sdspage
purifi
protein
migrat
kda
band
fig
lane
deglycosyl
protein
pngase
f
led
appear
kda
band
fig
lane
yield
recombin
purifi
protein
mgl
cultur
medium
determin
whether
protein
fragment
immunogen
antigen
formul
follow
manner
prior
subcutan
inject
mice
day
salin
alon
ii
alum
iii
alum
plu
cpg
odn
control
mice
immun
pb
alon
follow
immun
humor
sarscov
specif
immun
respons
assess
sera
total
sarscov
specif
igg
titer
day
determin
elisa
use
inactiv
sarscov
captur
antigen
contrast
pb
control
antigen
salin
alon
group
mice
immun
protein
formul
adjuv
show
detect
sarscov
specif
igg
titer
day
second
inject
titer
significantli
increas
day
p
fig
mice
immun
antigen
adjuv
alum
plu
cpg
odn
elicit
higher
antibodi
titer
p
mice
vaccin
antigen
plu
alum
day
howev
second
inject
total
sarscov
specif
serum
igg
titer
similar
mous
group
vaccin
adjuv
antigen
fig
sarscovspecif
igg
subclass
titer
determin
day
sera
elisa
evid
fig
mice
immun
antigen
plu
alum
elicit
predominantli
sarscovspecif
titer
wherea
combin
alum
cpg
odn
stimul
antibodi
product
line
elisa
data
sarscovspecif
serum
neutral
titer
significantli
higher
p
day
vaccin
group
receiv
alum
plu
cpg
odn
combin
compar
vaccin
group
receiv
antigen
alum
fig
second
inject
titer
increas
day
differ
two
vaccin
group
signific
fig
pbsvaccin
mice
mice
vaccin
antigen
salin
show
specif
serum
neutral
sarscov
determin
spike
protein
sarscov
could
recogn
sera
vaccin
mice
western
blot
analysi
perform
day
sera
use
sarscov
infect
cell
antigen
sera
recogn
kda
band
correspond
fulllength
spike
protein
fig
effect
sar
vaccin
induc
neutral
antibodi
prevent
sarscov
replic
mice
induc
cellular
immun
well
evalu
protein
specif
cellular
immun
respons
splenocyt
isol
vaccin
control
mice
antigenspecif
respons
measur
elispot
assay
indic
fig
vaccin
mice
formul
alum
plu
cpg
odn
result
nearli
threefold
increas
number
spot
compar
splenocyt
mice
immun
spike
protein
formul
alum
protein
specif
respons
splenocyt
also
evalu
elispot
assay
spot
observ
data
shown
sarscov
spike
protein
heavili
glycosyl
three
site
found
within
amino
acid
fragment
determin
whether
carbohydr
play
role
immunogen
protein
fragment
use
pngase
f
gener
mous
immun
shown
fig
protein
complet
deglycosyl
nativ
condit
procedur
sera
mice
vaccin
show
sarscovspecif
igg
titer
viru
neutral
activ
day
day
mice
show
detect
sarscovspecif
total
igg
elisa
titer
sarscov
neutral
antibodi
fig
c
howev
serum
titer
significantli
lower
p
mice
immun
protein
formul
adjuv
contrast
cellular
protein
specif
immun
respons
measur
number
cell
similar
mice
vaccin
either
glycosyl
deglycosyl
form
protein
fragment
fig
investig
antibodi
immun
respons
analyz
day
sera
two
group
vaccin
mice
use
protein
captur
antigen
elisa
shown
fig
mous
group
adjuv
alum
plu
cpg
odn
show
similar
igg
antibodi
level
antigen
addit
vaccin
mice
elicit
similar
igg
antibodi
immun
respons
antigen
contrast
vaccin
mice
elicit
higher
p
igg
antibodi
respons
protein
compar
protein
sarscov
shown
import
induc
host
respons
viru
neutral
activ
mediat
antibodi
consequ
much
attent
focus
protein
develop
sar
vaccin
compar
inactiv
sarscov
vectorbas
sar
vaccin
previous
report
develop
recombin
subunit
vaccin
elimin
safeti
risk
encount
vaccin
manufactur
administr
howev
disadvantag
recombin
subunit
vaccin
low
immunogen
poor
abil
gener
cellular
respons
present
studi
use
two
adjuv
aluminum
hydroxid
commonli
known
alum
cpg
odn
alum
extens
use
adjuv
commerci
vaccin
act
mainli
stimul
immun
respons
mechan
alum
produc
adjuv
effect
includ
format
antigen
depot
activ
antigenpres
cell
contrast
cpg
odn
bind
receptor
preferenti
induc
immun
respons
sever
report
shown
coadministr
alum
cpg
odn
antigen
enhanc
effect
cpg
odn
stimul
immun
respons
mechan
effect
investig
data
indic
cpg
odn
stimul
immun
respons
evidenc
increas
serum
titer
fig
secret
fig
magnitud
antibodi
respons
detect
increas
total
serum
sarscov
igg
titer
first
inject
cpg
odn
compar
alum
adjuv
alon
howev
second
inject
titer
similar
fig
c
result
suggest
cpg
odn
may
enhanc
primari
antibodi
respons
antigen
level
immun
reach
maxim
level
boost
possibl
previous
evalu
two
sar
vaccin
candid
mous
strain
use
studi
comparison
result
report
show
mice
vaccin
adjuv
alum
plu
cpg
odn
subunit
vaccin
show
higher
serum
neutral
antibodi
titer
mice
immun
recombin
adenovirus
express
nucleocapsid
protein
compar
viru
neutral
titer
mice
immun
wholekil
sarscov
vaccin
overal
geometr
titer
mean
induc
subunit
vaccin
much
higher
report
convalesc
sera
result
support
suggest
reach
maxim
titer
immun
boost
subunit
vaccin
ntermin
portion
sarscov
protein
attract
target
vaccin
develop
contain
receptorbind
domain
virusneutr
epitop
previous
suggest
propos
would
effect
safe
subunit
vaccin
sar
prevent
contrast
studi
et
al
vaccin
formul
differ
adjuv
test
rabbit
subunit
vaccin
evalu
murin
model
previous
demonstr
support
sarscov
replic
furthermor
protein
fragment
develop
et
al
fuse
human
fc
fragment
wherea
protein
use
studi
contain
four
addit
amino
acid
nterminu
studi
longer
polypeptid
produc
insect
cell
recombin
baculoviru
contrast
recombin
protein
produc
bioreactorbas
human
cell
cultur
system
technolog
base
human
cell
line
ideal
largescal
vaccin
manufactur
strength
cell
line
base
technolog
safeti
scalabl
product
addit
protein
produc
human
cell
close
resembl
natur
viral
protein
particularli
term
posttransl
modif
data
clearli
show
elicit
specif
antibodi
immun
respons
howev
sarscov
specif
total
igg
elisa
titer
viru
neutral
titer
lower
sera
vaccin
mice
fig
c
also
found
vaccin
vaccin
adjuv
alum
plu
cpg
odn
mice
show
similar
serum
igg
antibodi
level
antigen
fig
suggest
similar
immun
respons
reach
case
vaccin
candid
addit
vaccin
mice
elicit
similar
igg
antibodi
level
antigen
result
suggest
common
epitop
present
antigen
contrast
vaccin
mice
show
higher
igg
antibodi
level
result
suggest
contain
epitop
block
shield
carbohydr
sinc
observ
decreas
serum
neutral
titer
vaccin
mice
epitop
presum
lead
neutral
antibodi
respons
suggest
agreement
xray
crystal
structur
complex
show
three
nlink
oligosaccharid
posit
one
face
molecular
opposit
interact
face
summari
data
suggest
glycosyl
protein
import
vaccin
help
increas
amount
antibodi
direct
viru
neutral
epitop
shield
nonneutr
epitop
diseas
enhanc
immun
concern
develop
vaccin
particularli
true
sar
vaccin
sinc
increas
diseas
sever
observ
vaccin
felin
infecti
periton
viru
coronaviru
addit
synthet
version
variant
test
sensit
antibodi
neutral
pseudotyp
lentivirus
experi
antibodi
neutral
human
isolatesderiv
protein
enhanc
entri
mediat
civet
viru
protein
furthermor
liver
inflamm
found
mva
vaccin
ferret
challeng
sarscov
howev
report
advers
effect
laboratori
work
ferret
anim
rodent
monkey
sinc
mous
ideal
model
sar
assess
effect
immun
protein
fragment
diseas
enhanc
howev
issu
diseas
enhanc
care
studi
appropri
anim
model
becom
avail
final
demonstr
protein
fragment
formul
clinic
use
adjuv
alum
cpg
odn
elicit
strong
immun
respons
mice
plan
conduct
sarscov
challeng
experi
mice
ferret
studi
whether
vaccin
protect
sarscov
infect
